Greg Zante, Chief Financial Officer at Viking Therapeutics, Inc. (VKTX), sold 257,324 shares at $74.56 ($19.7M) on 2024-10-28, disclosed to the SEC on 2024-10-28.
Scheduled sale ($19.7M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $74.56 | 49,672 | $3.7M | 18.8% |
| 2 | $74.56 | 49,672 | $3.7M | 18.8% |
| 3 | $75.79 | 18,620 | $1.4M | 7.2% |
| 4 | $75.79 | 18,620 | $1.4M | 7.2% |
| 5 | $76.94 | 9,265 | $713K | 3.6% |
| 6 | $76.94 | 9,265 |
| $713K |
| 3.6% |
| 7 | $77.68 | 23,082 | $1.8M | 9.1% |
| 8 | $77.68 | 23,082 | $1.8M | 9.1% |
| 9 | $78.69 | 15,825 | $1.2M | 6.3% |
| 10 | $78.69 | 15,825 | $1.2M | 6.3% |
| 11 | $79.78 | 6,050 | $483K | 2.5% |
| 12 | $80.65 | 7,967 | $643K | 3.3% |
| 13 | $80.65 | 7,967 | $643K | 3.3% |
| 14 | $81.44 | 1,206 | $98K | 0.5% |
| 15 | $81.44 | 1,206 | $98K | 0.5% |
| Total | $76.54 avg | 257,324 | $19.7M | 100% |
| Filing → |
| VKTX | SELL | 2025-10-28 | $216K | — | Filing → |
| VKTX | SELL | 2025-07-03 | $237K | — | Filing → |
| VKTX | SELL | 2025-01-06 | $4.1M | — | Filing → |